Transforming Lives

Through a new class of safe, durable cancer treatments.

In The News

    • JUL 14 2017

    Musella Foundation Awards Oncoceutics New Research Grant

    The Musella Foundation recently awarded Oncoceutics a $25,000 research grant for a project titled “Clinical Evaluation of DRD5 as a Predictive Biomarker of Response to the selective DRD2 antagonist ONC201.” This will fund Oncoceutics’ work evaluating the impact of dopamine receptor expression on the responsiveness of patient tumors to ONC201, with a focus on glioblastoma